0001104659-21-088964.txt : 20210702 0001104659-21-088964.hdr.sgml : 20210702 20210702170140 ACCESSION NUMBER: 0001104659-21-088964 CONFORMED SUBMISSION TYPE: 424B5 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20210702 DATE AS OF CHANGE: 20210702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B5 SEC ACT: 1933 Act SEC FILE NUMBER: 333-230604 FILM NUMBER: 211071150 BUSINESS ADDRESS: STREET 1: 2 UNIVERSITY PLAZA STREET 2: SUITE 100 CITY: HACKENSACK STATE: NJ ZIP: 07601 BUSINESS PHONE: 201-696-9345 MAIL ADDRESS: STREET 1: 2 UNIVERSITY PLAZA STREET 2: SUITE 100 CITY: HACKENSACK STATE: NJ ZIP: 07601 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 424B5 1 tm2121220d2_424b5.htm 424B5

Supplement No. 1 dated July 2, 2021 to	Filed Pursuant to Rule 424(b)(5)
Prospectus Supplement dated October 1, 2020	Registration No. 333-230604
(To Prospectus dated April 12, 2019)

This Supplement No. 1 to Prospectus Supplement supplements and amends the Prospectus Supplement dated October 1, 2020 (the “ATM Prospectus Supplement”) filed by us. This Supplement No. 1 to the ATM Prospectus Supplement should be read in conjunction with the ATM Prospectus Supplement and the base prospectus dated April 12, 2019 (the “Base Prospectus”).

We have previously entered into an ATM Equity Offering Sales Agreement, dated October 1, 2020 (the “Sales Agreement”) with BofA Securities, Inc. (“BofA”) relating to our common stock (“Shares”), par value $0.001 per share.

We filed the ATM Prospectus Supplement to the Base Prospectus to register the offer and sale of our Shares from time to time through BofA, pursuant to the Sales Agreement, having an aggregate offering price of up to $30,000,000 (the “ATM Offering”).

We terminated the Sales Agreement on July 2, 2021. We sold a total of 3,296,123 Shares pursuant to the ATM Prospectus Supplement for total gross proceeds of approximately $13.8 million. The purpose of this Supplement No. 1 to the ATM Prospectus Supplement is to terminate the ATM Offering under the ATM Prospectus Supplement and the Base Prospectus, effective on the date of this Supplement No. 1 to the ATM Prospectus Supplement.

The date of this Supplement No. 1 is July 2, 2021

GRAPHIC 2 image_003.jpg GRAPHIC begin 644 image_003.jpg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end